{
  "meta": {
    "title": "Oncology_Basics_-_1_Etiology_Prevention_Of_Cancer",
    "url": "https://brainandscalpel.vercel.app/oncology-basics-1-etiology-prevention-of-cancer-47a12c61.html",
    "scrapedAt": "2025-11-29T18:25:01.398Z"
  },
  "questions": [
    {
      "id": 19793,
      "choices": [
        {
          "id": 79133,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lung </span></span></span></p>"
        },
        {
          "id": 79134,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prostate </span></span></span></p>"
        },
        {
          "id": 79135,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Colorectal </span></span></span></p>"
        },
        {
          "id": 79136,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pancreas</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which cancer site had the highest incidence rate among males in 2021?</span></span></span></p>",
      "unique_key": "Q7644128",
      "question_audio": null,
      "question_video": null,
      "map_id": 19704,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Prostate</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The table shows that prostate cancer had the highest percentage of new cases (26%) among males. While lung cancer is the leading cause of cancer deaths, it does not have the highest incidence rate.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Lung:&nbsp;</span></strong><span style=\"font-size:12.0pt\">While lung cancer is the leading cause of cancer deaths, it does not have the highest number of new cases (incidence) among males (12%).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Colorectal:</span></strong><span style=\"font-size:12.0pt\"> Colorectal cancer is the third most common (8%) cancer in men, but its incidence rate is lower than that of prostate cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Pancreas:</span></strong><span style=\"font-size:12.0pt\"> Pancreatic cancer is less common than prostate cancer, with a lower incidence rate.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prostate cancer screening and early detection are crucial for men&#39;s health.</span></span></span></p>",
      "correct_choice_id": 79134,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19799,
      "choices": [
        {
          "id": 79157,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Small cell lung cancer </span></span></span></p>"
        },
        {
          "id": 79158,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mesothelioma </span></span></span></p>"
        },
        {
          "id": 79159,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Squamous cell carcinoma of the lung </span></span></span></p>"
        },
        {
          "id": 79160,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Adenocarcinoma of the lung</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 50-year-old man, with a history of silicosis presents with progressive dyspnea and pleural plaques on imaging. Which of the following malignancies is he most likely at risk for developing in future?</span></span></span></p>",
      "unique_key": "Q2139793",
      "question_audio": null,
      "question_video": null,
      "map_id": 19710,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Mesothelioma</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Silicosis&nbsp;</span></strong><span style=\"font-size:12.0pt\">is a lung disease caused by inhaling silica dust. It&#39;s often found in occupations like mining, quarrying, and sandblasting.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Pleural plaques&nbsp;</span></strong><span style=\"font-size:12.0pt\">are thickening of the lining of the lungs (pleura) and are a hallmark of asbestos exposure.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Asbestos exposure&nbsp;</span></strong><span style=\"font-size:12.0pt\">is the primary risk factor for mesothelioma, a rare but aggressive cancer of the pleura.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Since the patient has both silicosis and pleural plaques, it strongly suggests a history of asbestos exposure, making mesothelioma the most likely future malignancy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Small cell lung cancer:</span></strong><span style=\"font-size:12.0pt\"> While smoking is the primary risk factor, it&#39;s not directly associated with silicosis or pleural plaques.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Squamous cell carcinoma of the lung:</span></strong><span style=\"font-size:12.0pt\"> Also primarily linked to smoking, not specifically to silicosis or asbestos.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Adenocarcinoma of the lung:</span></strong><span style=\"font-size:12.0pt\"> The most common type of lung cancer but not directly associated with silicosis or asbestos.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The combination of silicosis and pleural plaques is a strong indicator of asbestos exposure and significantly increases the risk of developing mesothelioma. Early detection and monitoring are crucial for individuals with this history.</span></span></p>",
      "correct_choice_id": 79158,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19800,
      "choices": [
        {
          "id": 79161,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Asbestos </span></span></span></p>"
        },
        {
          "id": 79162,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aflatoxin </span></span></span></p>"
        },
        {
          "id": 79163,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Arsenic </span></span></span></p>"
        },
        {
          "id": 79164,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Benzene</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A farmer from a developing country presents with jaundice, abdominal distention, and elevated alpha-fetoprotein (AFP) levels. Which of the following dietary contaminants is MOST likely associated with his suspected malignancy?</span></span></span></p>",
      "unique_key": "Q7424757",
      "question_audio": null,
      "question_video": null,
      "map_id": 19711,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Aflatoxin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aflatoxins are potent carcinogens produced by certain molds that can contaminate crops, particularly corn and peanuts. They are a significant risk factor for hepatocellular carcinoma (HCC) in developing countries where food storage practices may be inadequate.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Asbestos:&nbsp;</span></strong><span style=\"font-size:12.0pt\">While asbestos is a known carcinogen, it primarily affects the lungs and pleura, causing mesothelioma and lung cancer. It is not typically associated with hepatocellular carcinoma (HCC) or the symptoms presented by the farmer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Arsenic:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Arsenic exposure is linked to various cancers, including skin, bladder, and lung cancer. However, it is not the primary risk factor for HCC in the scenario described.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Benzene:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Benzene is an industrial solvent and a known carcinogen, primarily associated with leukemia and other blood cancers. It is not a major risk factor for HCC in the context of this patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aflatoxin contamination of food is a major global health concern and a significant risk factor for HCC.</span></span></p>",
      "correct_choice_id": 79162,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19801,
      "choices": [
        {
          "id": 79165,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">CEA </span></span></span></p>"
        },
        {
          "id": 79166,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">AFP </span></span></span></p>"
        },
        {
          "id": 79167,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">NSE </span></span></span></p>"
        },
        {
          "id": 79168,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">CA 19-9</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 55-year-old man with a history of smoking presents with cough, hemoptysis, and a lung mass on chest X-ray. Which of the following tumor markers is MOST likely to be elevated?</span></span></span></p>",
      "unique_key": "Q5904508",
      "question_audio": null,
      "question_video": null,
      "map_id": 19712,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) NSE</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">NSE is a marker for neuroendocrine tumors, including small cell lung cancer (SCLC). Its elevation in this scenario, along with the clinical presentation and imaging findings, supports the diagnosis of SCLC. The other markers are not typically associated with SCLC.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation</span></strong><span style=\"font-size:12.0pt\">: &nbsp;</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. CEA (Carcinoembryonic Antigen):&nbsp;</span></strong><span style=\"font-size:12.0pt\">While CEA can be elevated in some lung cancers, it&#39;s more commonly associated with colorectal, breast, and other gastrointestinal cancers.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. AFP (Alpha-fetoprotein):</span></strong><span style=\"font-size:12.0pt\"> AFP is primarily used as a marker for liver cancer (hepatocellular carcinoma) and certain germ cell tumors. It&#39;s not typically elevated in lung cancers.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. CA 19-9 (Carbohydrate Antigen 19-9):&nbsp;</span></strong><span style=\"font-size:12.0pt\">CA 19-9 is most commonly used as a marker for pancreatic cancer and some other gastrointestinal malignancies. It&#39;s not a primary marker for lung cancers.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">NSE is a useful marker for the diagnosis and monitoring of neuroendocrine tumors, particularly SCLC.</span></span></p>",
      "correct_choice_id": 79167,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19802,
      "choices": [
        {
          "id": 79169,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">CA 19-9 </span></span></span></p>"
        },
        {
          "id": 79170,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">CA-125 </span></span></span></p>"
        },
        {
          "id": 79171,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">PSA </span></span></span></p>"
        },
        {
          "id": 79172,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CD30</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 50-year-old man with chronic pancreatitis presents with jaundice and weight loss. Which tumor marker would be the MOST helpful in evaluating for a possible malignancy?</span></span></span></p>",
      "unique_key": "Q3422053",
      "question_audio": null,
      "question_video": null,
      "map_id": 19713,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) CA 19-9</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CA 19-9 is elevated in pancreatic cancer and can also be elevated in other conditions like pancreatitis. However, in the context of a patient with chronic pancreatitis presenting with concerning symptoms, elevated CA 19-9 would raise suspicion for pancreatic cancer and warrant further investigation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: &nbsp;</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. CA-125:&nbsp;</span></strong><span style=\"font-size:12.0pt\">This marker is primarily used for ovarian cancer and is not typically elevated in pancreatic cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. PSA:&nbsp;</span></strong><span style=\"font-size:12.0pt\">This marker is specific for prostate cancer and would not be helpful in evaluating for a pancreatic malignancy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. CD30:&nbsp;</span></strong><span style=\"font-size:12.0pt\">This marker is used in lymphoma diagnosis and is not relevant for pancreatic cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CA 19-9 can be a useful marker in evaluating for pancreatic cancer, especially in patients with risk factors like chronic pancreatitis.</span></span></p>",
      "correct_choice_id": 79169,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19794,
      "choices": [
        {
          "id": 79137,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lung cancer</span></span></span></p>"
        },
        {
          "id": 79138,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prostate cancer</span></span></span></p>"
        },
        {
          "id": 79139,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Colorectal cancer</span></span></span></p>"
        },
        {
          "id": 79140,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Liver cancer</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is the leading cause of cancer-related deaths in males worldwide?</span></span></p>",
      "unique_key": "Q1299333",
      "question_audio": null,
      "question_video": null,
      "map_id": 19705,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A) Lung cancer</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lung cancer is the leading cause of cancer-related deaths in males worldwide. It accounts for a significant proportion of cancer mortality due to its high incidence and poor prognosis. Lung cancer is often diagnosed at an advanced stage, which contributes to its high mortality rate.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B</strong>. Prostate cancer is a common cancer in males, but it generally has a better prognosis than lung cancer, and thus it is not the leading cause of cancer-related deaths.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C.&nbsp;</strong>Colorectal cancer is also a common cancer in males, but it is not the leading cause of cancer-related deaths.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D</span></strong><span style=\"font-size:12.0pt\">. Liver cancer is a significant cause of cancer-related deaths, but it is not the leading cause globally in males.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lung cancer is the leading cause of cancer-related deaths in males worldwide, due to its high incidence and poor prognosis.</span></span></p>",
      "correct_choice_id": 79137,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19795,
      "choices": [
        {
          "id": 79141,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">They are a safe alternative to smoking. </span></span></span></p>"
        },
        {
          "id": 79142,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">They are proven to cause lung cancer. </span></span></span></p>"
        },
        {
          "id": 79143,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Long-term cancer risks are unknown. </span></span></span></p>"
        },
        {
          "id": 79144,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">They only cause oral cancers.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements about e-cigarettes (vaping) is MOST accurate?</span></span></p>",
      "unique_key": "Q9328119",
      "question_audio": null,
      "question_video": null,
      "map_id": 19706,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Long-term cancer risks are unknown.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While e-cigarettes may be less harmful than traditional cigarettes, their long-term health effects, including cancer risk, are still under investigation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. They are a safe alternative to smoking.</span></strong><span style=\"font-size:12.0pt\"> E-cigarettes are not harmless. While they may expose users to fewer toxins than traditional cigarettes, they still contain potentially harmful chemicals like nicotine and heavy metals.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. They are proven to cause lung cancer.</span></strong><span style=\"font-size:12.0pt\"> While some studies have shown e-cigarettes contain carcinogenic substances, definitive long-term studies directly linking them to lung cancer are lacking. More research is needed.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. They only cause oral cancers.</span></strong><span style=\"font-size:12.0pt\"> While e-cigarettes expose the oral cavity to potentially harmful substances, their impact is not limited to this area. There are concerns about potential damage to the lungs and cardiovascular system as well.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">E-cigarettes are not harmless, and more research is needed to determine their long-term cancer risks.</span></span></p>",
      "correct_choice_id": 79143,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19796,
      "choices": [
        {
          "id": 79145,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">50% </span></span></span></p>"
        },
        {
          "id": 79146,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">80% </span></span></span></p>"
        },
        {
          "id": 79147,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">30%</span></span></span></p>"
        },
        {
          "id": 79148,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">10%</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Smoking is a major risk factor for various types of cancer. What percentage of cancer-related deaths are attributed to smoking?</span></span></span></p>",
      "unique_key": "Q3763422",
      "question_audio": null,
      "question_video": null,
      "map_id": 19707,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) 30%</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Smoking is estimated to be responsible for approximately 30% of all cancer deaths worldwide. It&#39;s a leading cause of preventable death and significantly increases the risk of developing various types of cancer, including lung, throat, esophagus, bladder, pancreas, and more.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Smoking cessation is crucial in reducing cancer-related deaths. It&#39;s never too late to quit, and the benefits of quitting can be seen relatively quickly after stopping smoking. </span><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Tobacco &ndash; single most important preventable cause of death in India .</span></strong></span></span></p>",
      "correct_choice_id": 79147,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19797,
      "choices": [
        {
          "id": 79149,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Human herpesvirus 8 (HHV-8) </span></span></span></p>"
        },
        {
          "id": 79150,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Epstein-Barr virus (EBV) </span></span></span></p>"
        },
        {
          "id": 79151,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Human papillomavirus (HPV) </span></span></span></p>"
        },
        {
          "id": 79152,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Human T-lymphotropic virus 1 (HTLV-1)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 35-year-old man with HIV presents with multiple violet-colored skin lesions and lymphadenopathy. The lesion is shown below. Which of the following is the most common etiological agent for his skin condition?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/06/screenshot-2024-08-06-162222.jpg\" style=\"height:199px; width:300px\" /></span></span></span></p>",
      "unique_key": "Q7163034",
      "question_audio": null,
      "question_video": null,
      "map_id": 19708,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A) Human herpesvirus 8 (HHV-8)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The presentation is consistent with Kaposi sarcoma (KS), a malignancy strongly associated with HHV-8 infection, particularly in immunocompromised individuals like those with HIV. While EBV can cause lymphoma, it doesn&#39;t typically present with skin lesions. HPV is linked to various cancers but not KS. HTLV-1 causes adult T-cell leukemia/lymphoma, which has a different presentation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Epstein-Barr virus (EBV):&nbsp;</span></strong><span style=\"font-size:12.0pt\">While EBV is associated with several malignancies (lymphoma, nasopharyngeal carcinoma), it doesn&#39;t typically cause the characteristic skin lesions seen in Kaposi sarcoma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Human papillomavirus (HPV):&nbsp;</span></strong><span style=\"font-size:12.0pt\">HPV is primarily associated with cervical cancer and other anogenital cancers. It doesn&#39;t cause the type of lesions seen in this patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Human T-lymphotropic virus 1 (HTLV-1):&nbsp;</span></strong><span style=\"font-size:12.0pt\">HTLV-1 is associated with adult T-cell leukemia/lymphoma, a type of blood cancer. It doesn&#39;t usually cause the distinctive skin lesions of Kaposi sarcoma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HHV-8 is the causative agent of Kaposi sarcoma, a malignancy often seen in HIV-infected individuals.</span></span></span></p>",
      "correct_choice_id": 79149,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ImageBased",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19798,
      "choices": [
        {
          "id": 79153,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">gamma rays </span></span></span></p>"
        },
        {
          "id": 79154,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">UVB </span></span></span></p>"
        },
        {
          "id": 79155,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">x-rays </span></span></span></p>"
        },
        {
          "id": 79156,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">alpha - rays</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following types of UV radiation is MOST strongly linked to the development of skin cancer?</span></span></span></p>",
      "unique_key": "Q8953046",
      "question_audio": null,
      "question_video": null,
      "map_id": 19709,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) UVB</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">UVB radiation is a type of ultraviolet radiation that has a shorter wavelength than UVA but a longer wavelength than UVC. It is the most damaging type of UV radiation that reaches the Earth&#39;s surface. UVB radiation is absorbed by the DNA in skin cells, causing damage that can lead to mutations and the development of skin cancer. &nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. gamma rays:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Gamma rays are a type of ionizing radiation with very short wavelengths and high energy. While they are carcinogenic, they are not the primary type of radiation associated with skin cancer. &nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. x-rays:&nbsp;</span></strong><span style=\"font-size:12.0pt\">X-rays are also a type of ionizing radiation with shorter wavelengths than UV radiation. They are used in medical imaging and can also be carcinogenic, but their primary association is not with skin cancer. &nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. alpha-rays:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Alpha rays are a type of particle radiation consisting of two protons and two neutrons. They have low penetrating power and are not associated with skin cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">UVB radiation is the most significant contributor to skin cancer development.</span></span></span></p>",
      "correct_choice_id": 79154,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53411,
      "choices": [
        {
          "id": 213125,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">CA 19-9 </span></span></span></p>"
        },
        {
          "id": 213126,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">CA 15-3 </span></span></span></p>"
        },
        {
          "id": 213127,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">CA-125 </span></span></span></p>"
        },
        {
          "id": 213128,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">CEA</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 45-year-old woman presents with a palpable breast mass and nipple discharge. Which tumor marker would be MOST appropriate to order in this scenario?</span></span></span></p>",
      "unique_key": "Q2796124",
      "question_audio": null,
      "question_video": null,
      "map_id": 25215,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) CA 15-3</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CA 15-3 is a tumor marker used to monitor breast cancer response to treatment and detect recurrence. While the other options are tumor markers, they are not typically used in the initial evaluation of a breast mass.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. CA 19-9:&nbsp;</span></strong><span style=\"font-size:12.0pt\">This marker is primarily associated with pancreatic cancer and some gastrointestinal malignancies. It&#39;s not routinely used in the initial evaluation of breast masses.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. CA-125:</span></strong><span style=\"font-size:12.0pt\"> This marker is primarily associated with ovarian cancer and is not routinely used in the evaluation of breast masses.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. CEA:</span></strong><span style=\"font-size:12.0pt\"> This marker can be elevated in various cancers, including breast cancer. However, it is not specific for breast cancer and is typically used to monitor response to treatment or detect recurrence rather than in the initial diagnosis of a breast mass.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CA 15-3 is a useful marker for monitoring breast cancer progression and treatment response.</span></span></span></p>",
      "correct_choice_id": 213126,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53412,
      "choices": [
        {
          "id": 213129,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">She has a 10-20% lifetime risk of developing breast cancer. </span></span></span></p>"
        },
        {
          "id": 213130,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">She has a 30-40% lifetime risk of developing breast cancer. </span></span></span></p>"
        },
        {
          "id": 213131,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">She has a 60-80% lifetime risk of developing breast cancer. </span></span></span></p>"
        },
        {
          "id": 213132,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">She has a 90-100% lifetime risk of developing breast cancer.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 35-year-old woman with a strong family history of breast and ovarian cancer undergoes genetic testing and is found to have a BRCA1 mutation. Which of the following statements is MOST accurate regarding her risk of developing breast cancer?</span></span></span></p>",
      "unique_key": "Q3928344",
      "question_audio": null,
      "question_video": null,
      "map_id": 25216,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) She has a 60-80% lifetime risk of developing breast cancer.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The passage states that women with BRCA1 mutations have a 60-80% lifetime risk of developing breast cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Women who inherit mutated alleles of these genes from either parent have at least a 60&ndash;80% lifetime chance of developing breast cancer and about a 33% chance of developing ovarian cancer. </span></span></p>",
      "correct_choice_id": 213131,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53413,
      "choices": [
        {
          "id": 213133,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Annual mammogram </span></span></span></p>"
        },
        {
          "id": 213134,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Annual MRI </span></span></span></p>"
        },
        {
          "id": 213135,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Biennial mammogram </span></span></span></p>"
        },
        {
          "id": 213136,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Clinical breast exam only</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 38-year-old woman with a BRCA1 mutation wants to know the best breast cancer screening approach for her. Which of the following is MOST appropriate?</span></span></span></p>",
      "unique_key": "Q9670362",
      "question_audio": null,
      "question_video": null,
      "map_id": 25217,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Annual MRI</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Women with BRCA1 or BRCA2 mutations have a significantly higher risk of breast cancer and should consider annual breast MRI in addition to mammograms. MRI is more sensitive for detecting breast cancer in high-risk women, especially those with dense breast tissue.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Annual mammogram:&nbsp;</span></strong><span style=\"font-size:12.0pt\">While mammograms are an important part of breast cancer screening, they are less sensitive than MRI in detecting cancer in women with BRCA mutations, especially those with dense breast tissue. &nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Biennial mammogram:&nbsp;</span></strong><span style=\"font-size:12.0pt\">The frequency is not sufficient for women with BRCA mutations, who are at higher risk and require more frequent screening. &nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Clinical breast exam only:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Clinical breast exams are important, but they are not enough for screening high-risk women. Imaging modalities like MRI are more effective for early detection.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Annual MRI (superior to MMG in high risk young female) is recommended for women with BRCA mutations due to their increased breast cancer risk.</span></span></span></p>",
      "correct_choice_id": 213134,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53414,
      "choices": [
        {
          "id": 213137,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Begin annual mammograms at age 40 </span></span></span></p>"
        },
        {
          "id": 213138,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Begin biennial mammograms at age 40 </span></span></span></p>"
        },
        {
          "id": 213139,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Begin annual mammograms at age 45 </span></span></span></p>"
        },
        {
          "id": 213140,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Begin biennial mammograms at age 50</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 40-year-old woman with a strong family history of breast cancer wants to know the recommended age to start breast cancer screening. According to the American Cancer Society (ACS), what is the MOST appropriate recommendation?</span></span></span></p>",
      "unique_key": "Q7914262",
      "question_audio": null,
      "question_video": null,
      "map_id": 25218,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Begin annual mammograms at age 45</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The ACS recommends that women at average risk start yearly mammograms at age 45. Women with a higher risk, such as a strong family history, may need to start screening earlier or have additional screening tests like MRI.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Begin annual mammograms at age 40:&nbsp;</span></strong><span style=\"font-size:12.0pt\">While some organizations recommend starting at age 40, the ACS specifically suggests starting annual screening at 45 for average-risk women.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Begin biennial mammograms at age 40:&nbsp;</span></strong><span style=\"font-size:12.0pt\">This option is less frequent than the ACS recommendation for average-risk women, and biennial screening might miss some early-stage cancers.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Begin biennial mammograms at age 50:&nbsp;</span></strong><span style=\"font-size:12.0pt\">This is the recommended starting age for biennial mammograms according to the U.S. Preventive Services Task Force (USPSTF), but the ACS recommends starting earlier for average-risk women and even earlier for women with increased risk due to family history.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The ACS recommends starting annual mammograms at age 45 for average-risk women.</span></span></p>",
      "correct_choice_id": 213139,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53415,
      "choices": [
        {
          "id": 213141,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bilateral salpingo-oophorectomy (rrBSO) </span></span></span></p>"
        },
        {
          "id": 213142,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Risk-reducing bilateral mastectomy (rrBLM) </span></span></span></p>"
        },
        {
          "id": 213143,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Annual mammogram starting at age 40 </span></span></span></p>"
        },
        {
          "id": 213144,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tamoxifen chemoprevention</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 32-year-old woman with a known BRCA1 mutation desires the most effective risk reduction strategy for breast cancer. Which of the following options would you recommend?</span></span></span></p>",
      "unique_key": "Q6957628",
      "question_audio": null,
      "question_video": null,
      "map_id": 25219,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Risk-reducing bilateral mastectomy (rrBLM)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The image indicates that rrBLM can reduce the risk of breast cancer by &ge; 90% in BRCA1/2 mutation carriers. While rrBSO reduces ovarian cancer risk, it doesn&#39;t directly address breast cancer risk. Mammography and chemoprevention are screening and risk reduction strategies, respectively, but not as effective as rrBLM in preventing breast cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Bilateral salpingo-oophorectomy (rrBSO):&nbsp;</span></strong><span style=\"font-size:12.0pt\">While rrBSO is a risk-reducing surgery, it primarily targets ovarian cancer risk. Although it can somewhat decrease breast cancer risk in premenopausal women, it is not as effective as rrBLM in directly addressing breast cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Annual mammogram starting at age 40:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Mammography is a screening tool for early detection, not a preventive measure. In women with BRCA1 mutations, who often develop breast cancer at a younger age, mammography alone may not be sufficient for early detection.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Tamoxifen chemoprevention:&nbsp;</span></strong><span style=\"font-size:12.0pt\">While tamoxifen can reduce the risk of breast cancer in women with BRCA2 mutations, its effectiveness is not as high as rrBLM in BRCA1 carriers. Additionally, it comes with potential side effects and is not suitable for all women.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">rrBLM is the most effective risk reduction strategy for breast cancer in BRCA1/2 mutation carriers.</span></span></span></p>",
      "correct_choice_id": 213142,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53416,
      "choices": [
        {
          "id": 213145,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">6 and 11 </span></span></span></p>"
        },
        {
          "id": 213146,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">16 and 18 </span></span></span></p>"
        },
        {
          "id": 213147,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">6, 11, and 16 </span></span></span></p>"
        },
        {
          "id": 213148,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">11, 16, and 18</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following HPV types are covered by BOTH Gardasil and Cervarix vaccines?</span></span></span></p>",
      "unique_key": "Q3387637",
      "question_audio": null,
      "question_video": null,
      "map_id": 25220,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) 16 and 18</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Gardasil covers HPV types 6, 11, 16, and 18, while Cervarix covers types 16 and 18. Therefore, both vaccines cover types 16 and 18.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HPV types 16 and 18 are high-risk types associated with a majority of cervical cancers, making their inclusion in both vaccines crucial.</span></span></span></p>",
      "correct_choice_id": 213146,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53417,
      "choices": [
        {
          "id": 213149,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Yes, she should continue with annual Pap smears. </span></span></span></p>"
        },
        {
          "id": 213150,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Yes, she should have a Pap smear every 3 years. </span></span></span></p>"
        },
        {
          "id": 213151,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Yes, she should have co-testing (Pap smear and HPV DNA test) every 5 years. </span></span></span></p>"
        },
        {
          "id": 213152,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">No, she does not require further screening.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 67-year-old woman has a history of negative Pap smears for the past 10 years and underwent a total hysterectomy for benign reasons. Does she require further cervical cancer screening?</span></span></span></p>",
      "unique_key": "Q7291140",
      "question_audio": null,
      "question_video": null,
      "map_id": 25221,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) No, she does not require further screening.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The image indicates that women over 65 with a history of negative screening in the last 10 years and a total hysterectomy for benign causes (no residual cervix) can stop screening.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Yes, she should continue with annual Pap smears:&nbsp;</span></strong><span style=\"font-size:12.0pt\">This is incorrect because the patient has a history of negative Pap smears for 10 years and had a total hysterectomy for benign reasons, which means her cervix was removed. There is no remaining cervical tissue to test.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Yes, she should have a Pap smear every 3 years:&nbsp;</span></strong><span style=\"font-size:12.0pt\">This is also incorrect for the same reasons as option A. There&#39;s no need for Pap smears if there&#39;s no cervix.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Yes, she should have co-testing (Pap smear and HPV DNA test) every 5 years:&nbsp;</span></strong><span style=\"font-size:12.0pt\">This is incorrect because co-testing is typically recommended for women aged 30-65. Since the patient is 67 and has a history of negative results, further testing is not necessary.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Women with a history of adequate negative screening and no cervix do not require further cervical cancer screening.</span></span></p>",
      "correct_choice_id": 213152,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "CriteriaBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53418,
      "choices": [
        {
          "id": 213153,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Immediately </span></span></span></p>"
        },
        {
          "id": 213154,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">At age 45 </span></span></span></p>"
        },
        {
          "id": 213155,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">At age 50 </span></span></span></p>"
        },
        {
          "id": 213156,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">10 years before her father&#39;s age of diagnosis (i.e., at age 45)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 40-year-old woman has a father who was diagnosed with colorectal cancer at age 55. When should she initiate screening for colorectal cancer, according to the image?</span></span></span></p>",
      "unique_key": "Q9496118",
      "question_audio": null,
      "question_video": null,
      "map_id": 25222,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) 10 years before her father&#39;s age of diagnosis (i.e., at age 45)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Individuals with a first-degree relative (FDR) diagnosed with CRC should begin screening 10 years before the earliest diagnosis in the FDR or </span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Age &ge; 40-45</span><span style=\"font-size:12.0pt\">. In this case, screening should start at age 45. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Immediately:&nbsp;</span></strong><span style=\"font-size:12.0pt\">While having a family history of colorectal cancer (CRC) does increase risk, immediate screening is not recommended unless there are other concerning symptoms or risk factors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. At age 45:&nbsp;</span></strong><span style=\"font-size:12.0pt\">This is the general recommended age to begin screening for those with average risk, but with a family history of CRC, earlier screening is appropriate.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. At age 50:&nbsp;</span></strong><span style=\"font-size:12.0pt\">This is too late for someone with a first-degree relative diagnosed with CRC at age 55. Earlier screening is necessary to detect potential problems early.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Individuals with a family history of colorectal cancer should start screening 10 years younger than the age at which their first-degree relative was diagnosed. This allows for early detection and intervention of precancerous polyps or early-stage cancer, ultimately improving outcomes.</span></span></span></p>",
      "correct_choice_id": 213156,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53419,
      "choices": [
        {
          "id": 213157,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">0 </span></span></span></p>"
        },
        {
          "id": 213158,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">1 </span></span></span></p>"
        },
        {
          "id": 213159,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">2 </span></span></span></p>"
        },
        {
          "id": 213160,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">3</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 65-year-old patient with metastatic lung cancer reports fatigue but is still able to perform most of their daily activities, including light housework and grocery shopping. Which ECOG performance status is MOST appropriate for this patient?</span></span></span></p>",
      "unique_key": "Q4549585",
      "question_audio": null,
      "question_video": null,
      "map_id": 25223,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) 1</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient can perform normal activities but with some effort due to fatigue. This aligns with ECOG PS 1, where strenuous activity is restricted, but the patient remains fully ambulatory.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/06/screenshot-2024-08-06-172340.jpg\" style=\"height:470px; width:1000px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ECOG PS 1 indicates a patient can carry out normal activity with effort, though strenuous activity is limited.</span></span></span></p>",
      "correct_choice_id": 213158,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "CriteriaBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}